Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.

IVAN Study Investigators, Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, Reeves BC.

Ophthalmology. 2012 Jul;119(7):1399-411. doi: 10.1016/j.ophtha.2012.04.015. Epub 2012 May 11. Erratum in: Ophthalmology. 2012 Aug;119(8):1508. Ophthalmology. 2013 Sep;120(9):1719.

PMID:
22578446
2.

Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.

Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS.

Cochrane Database Syst Rev. 2014 Aug 29;(8):CD005139. doi: 10.1002/14651858.CD005139.pub3. Review.

3.

Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration.

Moja L, Lucenteforte E, Kwag KH, Bertele V, Campomori A, Chakravarthy U, D'Amico R, Dickersin K, Kodjikian L, Lindsley K, Loke Y, Maguire M, Martin DF, Mugelli A, Mühlbauer B, Püntmann I, Reeves B, Rogers C, Schmucker C, Subramanian ML, Virgili G.

Cochrane Database Syst Rev. 2014 Sep 15;(9):CD011230. doi: 10.1002/14651858.CD011230.pub2. Review.

4.

Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.

Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E.

Cochrane Database Syst Rev. 2017 Jun 22;6:CD007419. doi: 10.1002/14651858.CD007419.pub5. Review.

PMID:
28639415
5.

Aflibercept for neovascular age-related macular degeneration.

Sarwar S, Clearfield E, Soliman MK, Sadiq MA, Baldwin AJ, Hanout M, Agarwal A, Sepah YJ, Do DV, Nguyen QD.

Cochrane Database Syst Rev. 2016 Feb 8;2:CD011346. doi: 10.1002/14651858.CD011346.pub2. Review.

6.

Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia.

Zhu Y, Zhang T, Xu G, Peng L.

Cochrane Database Syst Rev. 2016 Dec 15;12:CD011160. doi: 10.1002/14651858.CD011160.pub2. Review.

PMID:
27977064
7.

Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.

Mitry D, Bunce C, Charteris D.

Cochrane Database Syst Rev. 2013 Jan 31;(1):CD009510. doi: 10.1002/14651858.CD009510.pub2. Review.

PMID:
23440840
8.

Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis.

Ba J, Peng RS, Xu D, Li YH, Shi H, Wang Q, Yu J.

Drug Des Devel Ther. 2015 Sep 28;9:5397-405. doi: 10.2147/DDDT.S86269. eCollection 2015. Review.

9.

Long-term follow-up of vascular endothelial growth factor inhibitor therapy for neovascular age-related macular degeneration.

Scott AW, Bressler SB.

Curr Opin Ophthalmol. 2013 May;24(3):190-6. doi: 10.1097/ICU.0b013e32835fefee. Review.

PMID:
23492430
10.

Ocular and systemic safety of bevacizumab and ranibizumab in patients with neovascular age-related macular degeneration.

Johnson D, Sharma S.

Curr Opin Ophthalmol. 2013 May;24(3):205-12. doi: 10.1097/ICU.0b013e32835f8ec0. Review.

PMID:
23518613
11.

Bevacizumab and ranibizumab for neovascular age-related macular degeneration: an updated meta-analysis of randomised clinical trials.

Kodjikian L, Decullier E, Souied EH, Girmens JF, Durand EE, Chapuis FR, Huot L.

Graefes Arch Clin Exp Ophthalmol. 2014 Oct;252(10):1529-37. doi: 10.1007/s00417-014-2764-6. Epub 2014 Aug 22. Review.

12.

The Clinical Effectiveness of Ranibizumab Treat and Extend Regimen in nAMD: Systematic Review and Network Meta-Analysis.

Danyliv A, Glanville J, McCool R, Ferreira A, Skelly A, Jacob RP.

Adv Ther. 2017 Mar;34(3):611-619. doi: 10.1007/s12325-017-0484-0. Epub 2017 Feb 10. Review. Erratum in: Adv Ther. 2017 May;34(5):1233.

13.

Anti-VEGF therapies and blood pressure: more than meets the eye.

Enseleit F, Michels S, Ruschitzka F.

Curr Hypertens Rep. 2010 Feb;12(1):33-8. doi: 10.1007/s11906-009-0082-x. Review.

PMID:
20425156
14.

Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines.

Kaiser PK, Cruess AF, Bogaert P, Khunti K, Kelly SP.

Graefes Arch Clin Exp Ophthalmol. 2012 Nov;250(11):1563-71. doi: 10.1007/s00417-012-2123-4. Epub 2012 Aug 12. Review. Erratum in: Graefes Arch Clin Exp Ophthalmol. 2013 Feb;251(2):625-6.

15.

Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence?

Ziemssen F, Grisanti S, Bartz-Schmidt KU, Spitzer MS.

Drugs Aging. 2009;26(4):295-320. doi: 10.2165/00002512-200926040-00002. Review.

PMID:
19476398
18.

Anti-VEGF Agents and the Risk of Arteriothrombotic Events.

Zarbin MA.

Asia Pac J Ophthalmol (Phila). 2018 Jan-Feb;7(1):63-67. doi: 10.22608/APO.2017495. Epub 2018 Feb 1. Review.

19.

Tracing the natural course of visual acuity and quality of life in neovascular age-related macular degeneration: a systematic review and quality of life study.

Elshout M, Webers CA, van der Reis MI, de Jong-Hesse Y, Schouten JS.

BMC Ophthalmol. 2017 Jul 11;17(1):120. doi: 10.1186/s12886-017-0514-3. Review.

20.

Extended Duration Vascular Endothelial Growth Factor Inhibition in the Eye: Failures, Successes, and Future Possibilities.

Stewart MW.

Pharmaceutics. 2018 Jan 27;10(1). pii: E21. doi: 10.3390/pharmaceutics10010021. Review.

Supplemental Content

Support Center